“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at standard treatment with or without celecoxib for transitional cell bladder cancer (BOXIT)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at celecoxib for a very early type of bladder cancer called superficial transitional cell bladder cancer. It was supported by Cancer Research UK.
More about this trial
- whether adding celecoxib to standard treatment helps stop bladder cancer coming back
- more about the side effects of celecoxib
Summary of results
- 236 people had celecoxib tablets twice a day for 2 years
- 236 people had dummy (placebo) tablets twice a day for 2 years
The research team looked at how many people’s cancer had started to grow again 3 years after joining the trial. They found it was similar in the two groups:
- 76 people (32%) who’d had celecoxib
- 86 people (36%) who’d had the placebo
When they looked at how many people had died, it was also similar in the two groups:
- 26 people (11%) who’d had celecoxib
- 21 people (9%) who’d had the placebo
About 8 out of 10 people had at least one side effect, but many were mild or didn’t last long. About 3 out of 10 people in each group had a more severe side effect including tummy (abdominal) pain, difficulty sleeping and needing to pass urine more often than usual.
- 12 people (5%) who had celecoxib
- 4 people (2%) who had the placebo
- the results so far showed that it was unlikely people would have any benefit from taking celecoxib
- there was a small increased risk of heart related side effects
How to join a clinical trial
Prof. J Kelly
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Kyowa Hakko UK Limited
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/07/004.